Expression data from Saccharomyces cerevisiae to evaluate the impact of suppressors of Aβ42 cytotoxicity on recombinant protein production

High-level production of pharmaceutical proteins in industrial microorganism is often limited due to the increased cellular stress from misfolded proteins or protein aggregates. Here, we explore the feasibility of applying a yeast Alzheimer’s disease (AD) model with accumulation of amyloid-β peptides (Aβ42), which presents similar phenotypes of cellular stress. We utilize the suppressors of Aβ42 cytotoxicity as potential metabolic engineering targets to improve industrial protein production. The transcriptomics analyses provide new insights towards developing synthetic yeast cell factories for biosynthesis of valuable pharmaceutical proteins.工业微生物中药物蛋白的高水平生产常因错误折叠蛋白或蛋白聚集引发的细胞应激增强而受到限制。本研究探究了构建并应用一种可积累淀粉样β肽（amyloid-β peptides, Aβ42）的酵母阿尔茨海默病（Alzheimer’s disease, AD）模型的可行性，该模型可呈现与细胞应激相关的相似表型。我们将Aβ42细胞毒性的抑制因子作为潜在代谢工程靶点，以提升工业蛋白的生产水平。转录组学分析为开发用于合成高价值药用蛋白的合成酵母细胞工厂提供了全新的研究视角。